الشرق الأوسط
الشرق الأوسط
Ready to play
Ready to play
Egypt is currently experiencing a shortage of insulin used to treat diabetes patients. This comes alongside statements from the Minister of Health indicating that certain types of insulin will not be imported as part of government cost-cutting policies, while emphasizing that insulin remains available in the local market and is being boosted through domestic production. The government relies on highly effective local alternatives, with approximately 95% of pharmaceutical demand in the domestic market being met through local manufacturing. However, some patients continue to reject Egyptian products due to beliefs that they are less effective, despite their availability and exports to other countries. Patients are calling on relevant authorities to provide medicines specifically for children and blood glucose monitoring devices, as the monthly treatment cost can reach up to 8,000 Egyptian pounds. Additionally, tensions between doctors and patients over a preference for imported insulin over Egyptian-made options persist, partly because of patient doubts. Nonetheless, experts affirm that domestic medicines are equivalent in effectiveness to imported ones.
Notice: This Is an AI-Generated Summary
Comments (0)